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Screening of antenatal clinic attendees is central to mon-
itoring the human immunodefi ciency virus (HIV) epi-
demic. However, recent evidence suggests that declining 
fertility rates are affecting the reliability of antenatal 
clinic surveys as the epidemic matures. Population-based 
HIV surveys, while ideal, are resource-intensive, necessi-
tating newer, cost-effective approaches. Unlinked anon-
ymous testing for HIV in sputum of tuberculosis (TB) 
patients serves as reliable proxy for estimating the bur-
den of symptomatic HIV disease and is a potential ad-
junct to current surveillance efforts. Unlinked anony-
mous testing for HIV surveillance in KwaZulu-Natal, 
South Africa, the epicentre of the global epidemic, is jus-
tifi ed, as data from the largest urban TB referral clinic 
indicate that only 22% of TB patients uptake voluntary 
HIV testing.
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DISEASE SURVEILLANCE is an important founda-
tion of public health decision-making and the main-
stay of infectious disease management. To effectively 
design and target health interventions, it is necessary 
to quantify the magnitude of a disease, monitor tem-
poral trends and identify risk factors.1 
In regions where heterosexual human immuno-
defi ciency virus (HIV) transmission is the primary 
mode of transmission, or in a generalised epidemic 
such as in sub-Saharan Africa, the screening of ante-
natal clinic attendees is central to monitoring the 
evolving epidemic.1–3 Pregnant women have served as 
a reliable proxy marker of HIV risk in the general 
population.1,2 However, recent evidence suggests that 
fertility rates are declining as the HIV epidemic ma-
tures, resulting in an underestimation and declining 
reliability of antenatal clinic surveys.2 Tuberculosis 
(TB) is a common presentation of symptomatic HIV 
disease. Given the TB-HIV co-infection rate of 65%,4 
and the 10% per annum risk of incident TB in HIV-
infected individuals,4 it is reasonable to extrapolate 
that TB refl ects the burden of symptomatic HIV dis-
ease. We therefore suggest that, in addition to HIV 
surveillance in antenatal clinics, we expand HIV sur-
veillance to TB patients as well. This will serve as a 
marker of the burden of symptomatic HIV disease, 
rather than HIV infection, in a TB-HIV endemic 
population. Although there has been an increase in 
population-based HIV prevalence and incidence rate 
data, this approach is prohibitively resource-intensive 
in most settings.5 Newer approaches that are less in-
vasive or labour-intensive, with the added benefi t of 
rapid data turnover such as HIV sputum testing, have 
demonstrated effi cacy.3
In a maturing HIV epidemic in which morbidity 
and mortality will continue to increase until treat-
ment coverage improves, there is a critical need to ex-
pand surveillance systems to monitor trends and the 
impact of antiretroviral (ARV) provision on HIV re-
lated comorbidities. TB is the most common oppor-
tunistic infection associated with HIV disease progres-
sion; therefore, monitoring the trends of HIV infection 
in TB patients provides a logical, reliable marker for 
estimating morbidity trends, projecting more precisely 
the short- to medium-term care needs and measuring 
the impact of ARVs on TB disease burden. The im-
pact of ARVs on TB incidence has been modelled pre-
viously, and it is estimated that by initiating ARVs at 
CD4 < 200 cells/mm3 the cumulative incidence of TB 
would decrease by 22% over 20 years, and at CD4 < 
500 cells/mm3 by 50%.6 This impact not only re-
duces the risk of TB, it also extends life expectancy, 
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secretions has been demonstrated in Botswana.3 This 
expansion allows enhancement of current antenatal 
clinic-based HIV surveillance in the setting of a gen-
eralised epidemic, enables comparison of data from 
linked to unlinked HIV testing and offers an under-
standing of who is volunteering to test vs. who needs 
to test. This comparison may provide evidence for jus-
tifying PIT in TB services as well as more accurately 
assessing the impact of HAART on AIDS-related co-
morbidity. Unlinked anonymous testing does have 
limitations, which include an inability to distinguish 
incident from prevalent TB, diffi culty in distinguishing 
sputum taken for diagnosis vs. monitoring of treat-
ment outcomes and the need to include clinical de-
tails on the sputum requisition form.
Statistics for KZN indicate an HIV prevalence of 
37.4% compared to 28% nationally, and an incidence 
of TB of 1094 per 100 000 population as compared 
to 740 nationally.8 Current World Health Organiza-
tion (WHO) guidelines recommend a target rate of 
80% for routine HIV surveillance of TB patients to 
provide a robust estimate of the TB-HIV burden. 
However, the availability of policy does not equate to 
coverage or utilisation. Data from other developing 
countries, Uganda and Kenya, indicate that they are 
meeting WHO recommendations for HIV surveillance 
in TB populations through voluntary testing.9,10 This 
is in contrast to KZN, South Africa, the epicentre of 
the HIV pandemic and the nation with the fi fth high-
est TB burden. In KZN, with high dual infection rates 
and a low uptake of VCT, the use of unlinked anon-
ymous testing in TB patients is justifi ed for obtain-
ing HIV surveillance data and epidemiological anal-
ysis. HIV testing of leftover sputum samples could 
serve as a useful and reliable tool for obtaining such 
data. Ultimately, effective surveillance is a fundamen-
tal means of working towards and ensuring full ac-
cess to comprehensive HIV services.
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The data refl ected in Table 1, derived from the 
largest urban TB referral clinic in KwaZulu-Natal 
(KZN), the epicentre of the HIV epidemic, shows 
that approximately 22% of confi rmed TB patients 
accepted provider-initiated testing (PIT) during 2007. 
While this is a three-fold increase compared with 2004, 
when only voluntary counselling and testing (VCT) 
was available, this remains signifi cantly below data 
reported elsewhere. Years of fear and stigma continue 
to pose a major obstacle to individuals deciding 
whether or not to have a HIV test.
Data from a specialist TB referral hospital in the 
same area indicate that in-patients are more likely to 
test for HIV (Table 2) compared to out-patients from 
the TB clinic. This is likely related to a trust relation-
ship established during the protracted period of time 
spent in hospital, as opposed to in an out-patient 
setting. 
International guidelines recommend PIT for HIV 
in high-risk patients such as TB suspects.*1,2 The ad-
dition of the TB clinic population to HIV surveillance 
systems would enable two endeavours key to re-
sponding effectively to TB and HIV: the estimation of 
the HIV prevalence in TB patients, the group most 
easily identifi able to benefi t from highly active anti-
retroviral treatment initiation (HAART), and the at-
tributable fraction of the increasing TB caseload due 
to HIV infection. It would also be a marker of HIV 
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TB in HIV-infected individuals due to paucibacillary 
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sociated with sputum culture to exclude TB.
Unlinked anonymous HIV testing1 has been pre-
viously performed on blood specimens, but it can 
also be performed less invasively on ‘leftover’ sputum 
samples collected for microscopy. The comparable 
specifi city and sensitivity between serum and sputum 
Table 1 Trends in HIV testing in TB patients in an urban TB 








2004 8716  770 (8.8)
2005 8567 1145 (13.4)
2006 8180 1392 (17.0)
2007 7202 1564 (21.7)
P < 0.0001 (χ2 for trend)
HIV = human immunodefi ciency virus; TB = tuberculosis.
* TB suspects refer to anyone that attends the clinic because of 
signs and symptoms suggestive of TB
Table 2 Trends in HIV testing in TB patients in a specialist 







2004  609  367 (60.3)
2005  893  527 (59.0)
2006  935  681 (72.8)
2007 1509 1296 (85.9)
2008 1489 1321 (88.7)
P < 0.0001 (χ2 for trend)
HIV = human immunodefi ciency virus; TB = tuberculosis.
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R É S U M É
Dans les régions, comme l’Afrique subsaharienne, où 
l’épidémie de l’infection par le virus de l’immunodéfi cience 
humaine (VIH) est généralisée, le dépistage des clientes 
fréquentant les cliniques prénatales est essentiel pour le 
suivi de l’évolution de l’épidémie. Toutefois, des données 
récentes suggèrent qu’avec la maturation de l’épidémie, 
la décroissance des taux de fertilité affecte la fi abilité des 
enquêtes des cliniques prénatales. Les enquêtes VIH ba-
sées sur la population, bien qu’étant idéales, exigent des 
ressources considérables et prohibitives, d’où la néces-
sité d’approches nouvelles moins invasives et requérant 
moins de travail. La recherche anonyme et dissociée du 
VIH dans les crachats des patients tuberculeux peut 
constituer un substitut fi able concernant le fardeau de la 
maladie VIH symptomatique et un adjoint potentiel aux 
efforts actuels de surveillance. La recherche anonyme et 
dissociée pour la surveillance du VIH au KwaZulu-N atal, 
l’épicentre de l’épidémie mondiale, se justifi e car les don-
nées de la plus grande clinique urbaine de référence TB 
indiquent que 22% seulement des patients tuberculeux 
recourent à un test volontaire du VIH.
R E S U M E N
La detección sistemática de la infección por el virus de 
la inmunodefi ciencia humana (VIH) en las mujeres que 
acuden a las consultas de control del embarazo es esen-
cial en la supervisión de la epidemia de esta enfermedad. 
Sin embargo, datos recientes indican que a medida que 
la epidemia progresa, las tasas decrecientes de fertilidad 
afectan la fi abilidad de las encuestas en las consultas de 
control del embarazo. Las encuestas poblacionales sobre 
el VIH constituyen un instrumento ideal, pero al mismo 
tiempo exigen gran cantidad de recursos ; por esta razón 
se precisan nuevos enfoques más rentables. La reali-
zación anónima y desligada de una prueba para el VIH 
en el esputo de pacientes con tuberculosis (TB) sirve 
como un indicador sustitutivo fi able de la carga de mor-
bilidad por infección sintomática causada por el VIH y 
constituyen un complemento posible a las campañas vi-
gentes de vigilancia. La prueba desligada y anónima en 
la vigilancia de la infección por el VIH en KwaZulu-
N atal, el epicentro de la epidemia mundial, está justifi -
cada pues los datos de los principales consultorios de 
referencia de tuberculosis indican que solo el 22% de los 
pacientes con TB realiza la prueba voluntaria de diag-
nóstico de la infección por VIH.
